Repair Stem Cells vs. Cardio Vascular Diseases

VesCell was the first company in the world (2005) to successfully treat heart patients with stem cells. Still today, with 350 successes out of 500 treated patients (70%), cardiologists repeat the nonsense that stem cells are unproven. They advise their patients---100% of whom are worse off after years of useless pills than they were when they were first diagnosed---to stay with them and their 0% success.

Below are seven peer-reviewed scientific papers showing that VesCell's results are infinitely better than toxic pills. Pick the one(s) that apply to you, download them, and feel free to pass them on to the 0% experts when they attempt to give you their made-up stories about stem cells.

To determine the efficacy of intramyocardial injection of angiogenic cell precursors in nonischemic dilated cardiomyopathy, 35 patients with nonischemic dilated cardiomyopathy underwent injections of angiogenic cell precursors into the left ventricle. A control group of 17 matching patients were treated medically, i.e. with standard cardiology.

Clinical trial illustrates the safety and efficacy of VesCell Repair Stem Cell treatment. Accepted by the American Heart Assn in 2005-6. This trial was a key element in attaining regulatory approval for the treatment protocol that improved the lives of 300 mostly "no-option" heart patients.

Research paper shows that peripheral blood derived stem cells can differentiate into a variety of other stem cells (angiogenic, myocardial and neural lineages) and do so in sufficient quantities to use as autologous treatment for a variety of diseases.

Bioprocessing Journal scientific paper shows the consistent and reliable manufacturing procedure utilized by VesCell for transforming bone marrow and blood-derived stem cells into angiogenic cell precursors (ACPs) and hematopoietic stem cell (HSC) cellular products for the treatment of severe heart diseases.  End product was found to be a) safe and effective; b) prepared from non-mobilized peripheral blood; c) stable, with a relatively long shelf-life; and d) ready-to-use and easily utilized by the physician.

Clinical study at Chao Phya Hospital Heart Center and Siriraj Hospital H.M. Cardiac Center clinical study shows that transcoronary injection of angiogenic cells precursors improved cardiac/left ventricular ejection fraction (LVEF), exercise capacity and quality of life with high safety profile for 70% of ischemic cardiomyopathy patients with no-option revascularization.

Bangkok Heart Hospital and U of Pittsburgh Medical Center/McGowan Institute for Regenerative Medicine clinical trial shows that VesCell type expanded autologous blood derived stem cells utilized in intramyocardial transplantation is feasible and safe in severely ill patients with intractable heart failure in all cases of dilated cardiomyopathy (DCM) and in both first-time and “redo” ischemic cardiomyopathy (ICM) patients.

Shows the safety, and feasibility and enhancement of limb salvage from implantation of non-mobilized peripheral blood angiogenic cell precursors (NMPB-ACPs) in 80% of patients with critical limb ischemia (CLI) who were poor candidates for standard revascularization treatment options.

One of the earliest studies (2003) by the Western Hemisphere's #1 stem cell cardiologist, Dr. Roberto Fernandez-Vina of Argentina. The paper shows how ejection fractions improved over time after stem cells.

Showing improvements in heart function, quality of life, and mortality due to stem cells vs. standard cardiology. Abstract..

The first major AMI trial was a huge success, with only two negative events among the 100 ASC patients vs 12 in the control group. The anti-ASC lobby tried hard to make light of it (NEJM 20 Sep 2006) but were crushed by virtually every following AMI trial which proved Zeiher correct.